Immune Thrombocytopenia

Immune thrombocytopenia (ITP) is an acquired autoimmune disorder in which antibody- and cell-mediated mechanisms cause both increased destruction and reduced production of platelets, resulting in a low platelet count and a risk of bleeding. It is diagnosed largely by excluding other causes of thrombocytopenia, and it may be primary (with no identifiable cause) or secondary to another condition.

Definition

Immune thrombocytopenia is an autoimmune disorder characterized by isolated thrombocytopenia due to immune-mediated platelet destruction and impaired platelet production, diagnosed by excluding other causes of a low platelet count.

Scope

This entry covers the definition and classification of ITP (primary versus secondary; newly diagnosed, persistent, and chronic), the immune mechanisms of platelet destruction and impaired production, and the diagnosis-of-exclusion approach. It is a reference topic in immunohematology and does not provide treatment regimens.

Core questions

• How do immune mechanisms lower the platelet count in ITP?
• Why is ITP largely a diagnosis of exclusion?
• What distinguishes primary from secondary ITP?
• How are the phases of ITP defined over time?

Key concepts

• Anti-platelet autoantibodies (often anti-GPIIb/IIIa)
• Accelerated platelet destruction
• Impaired megakaryocyte platelet production
• Primary vs secondary ITP
• Newly diagnosed, persistent, and chronic phases
• Diagnosis of exclusion
• Bleeding risk and platelet count

Mechanisms

In ITP, autoantibodies — commonly directed against platelet surface glycoproteins such as GPIIb/IIIa — opsonize platelets, which are then cleared by Fc-receptor-bearing macrophages, chiefly in the spleen. Beyond accelerated destruction, the same autoimmune process can impair platelet production by affecting megakaryocytes, and T-cell-mediated mechanisms contribute to the loss of immune tolerance. The result is a platelet count low enough to risk bleeding. ITP is termed primary when no underlying cause is found and secondary when it accompanies conditions such as autoimmune disease, infection, lymphoproliferative disorders, or certain drugs.

Clinical relevance

ITP is a leading cause of isolated immune-mediated thrombocytopenia, and understanding its mechanisms clarifies why it is diagnosed by excluding other causes and why both platelet destruction and underproduction matter. This entry is educational; it explains the disorder without recommending specific therapies, which are individualized and guided by current clinical guidelines.

Epidemiology

ITP occurs in both children and adults. In children it is often acute and self-limited, frequently following an infection, whereas in adults it more often follows a chronic course. Estimates of incidence and prevalence vary with case definition, reflecting that ITP is defined partly by the exclusion of other causes of thrombocytopenia.

History

The recognition that idiopathic thrombocytopenic purpura is immune-mediated dates to the mid-twentieth century, when Harrington's experiments demonstrated a plasma factor capable of inducing thrombocytopenia, implicating circulating anti-platelet antibodies. Subsequent decades clarified the dual roles of platelet destruction and impaired production and led to standardized terminology and consensus diagnostic criteria for primary immune thrombocytopenia.

Debates

How should the phases and treatment thresholds of ITP be defined?

Consensus and guideline groups have worked to standardize the terminology of newly diagnosed, persistent, and chronic ITP and to clarify when treatment is warranted, an area that continues to be refined as evidence accrues.

Key figures

• Paul Kaznelson
• William Harrington
• Douglas Cines
• James Bussel
• Drew Provan

Seminal works

• provan-2019
• neunert-2020

Frequently asked questions

Why is immune thrombocytopenia called a diagnosis of exclusion?

There is no single confirmatory test for ITP, so it is diagnosed by finding isolated thrombocytopenia and ruling out other causes such as drugs, infections, bone-marrow disorders, and other autoimmune conditions.

Is ITP only caused by platelet destruction?

No. Although accelerated immune destruction of platelets is central, ITP also involves impaired platelet production by megakaryocytes, which is why both mechanisms are considered in understanding the disease.